JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Molecular Cloning and Characterization of Bovine CYP26A1 Promoter
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : Journal of Life Science
  • Volume 26, Issue 1,  2016, pp.42-49
  • Publisher : Korean Society of Life Science
  • DOI : 10.5352/JLS.2016.26.1.42
 Title & Authors
Molecular Cloning and Characterization of Bovine CYP26A1 Promoter
Kwak, Inseok;
  PDF(new window)
 Abstract
The retinoic acid (RA) plays an important role in the growth and development of many cells, and bioactive RA concentration is regulated by several enzymes, including CYP26A1. The expression of the CYP26A1 gene is regulated by RA, and the CYP26A1 gene is one of the candidates for RA-responsive genes. Although CYP26A1 genes are cloned from several animals, cloning of the CYP26A1 gene from cows has not been reported yet. The promoter region of CYP26A1 from cows was cloned by PCR and analyzed by sequence alignment with human and mouse CYP26A1. The RA-responsive element (RARE), DR-5 (ttggg), was located in this region and was perfectly conserved. The promoter region of bovine CYP26A1, which contains DR-5, was ligated to the luciferase reporter gene on transient transfection assays. The expression of CYP26A1-Luc promoter was activated by ATRA treatment in lung-derived mtCC cells. Co-transfection with RAR-α or -β with ATRA significantly activates the expression of CYP26A1-Luc promoter; however, it was less effective with either RAR-γ or RXR-γ. In addition, the endogenous gene expressions measured by Q-RT-PCR in mtCC cells were not significantly affected by ATRA treatment for 2 days; however, the expression of the endogenous CYP26A1 gene was diminished sharply at day 3 with ATRA treatment. In conclusion, the promoter region of bovine CYP26A1 contains conserved DR-5 RARE, which functions as a binding site for RAR-α or -β, and it is involved in the regulation of CYP26A1 gene expression and the control of RA signaling in mtCC cells.
 Keywords
ATRA;CYP26A1;RAR;RARE (responsive element);RXR;
 Language
English
 Cited by
 References
1.
Aboulafia, D. M., Norris, D., Henry, D., Grossman, R. J., Thommes, J., Bundow, D., Yocum, R. C. and Stevens, V. 2003. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch. Dermatol. 139, 178-186.

2.
Abu-Abed, S., Dollé, P., Metzger, D., Beckett, B., Chambon, P. and Petkovich, M. 2001. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev. 15, 226-240. crossref(new window)

3.
Aranda, A. and Pascual, A. 2001. Nuclear hormone receptors and gene expression. Physiol. Rev. 81, 1269-1304.

4.
Arrieta, Ó., Hernández-Pedro, N., Fernández-González-Aragón, M. C., Saavedra-Pérez, D., Campos-Parra, A. D., Ríos-Trejo, M. Á., Cerón-Lizárraga, T., Martínez-Barrera, L., Pineda, B., Ordóñez, G., Ortiz-Plata, A., Granados-Soto, V. and Sotelo, J. 2011. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 77, 987-995. crossref(new window)

5.
Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D. and Moore, D. D. 1994. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol. Cell. Biol. 14, 1544-1552. crossref(new window)

6.
Bushue, N. and Wan, Y. J. 2010. Retinoid pathway and cancer therapeutics. Adv. Drug. Deliv. Rev. 62, 1285-1298. crossref(new window)

7.
Chambon, P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954.

8.
Chawla, A., Repa, J. J., Evans, R. M. and Mangelsdorf, D. J. 2001. Nuclear receptors and lipid physiology: Opening the X-files. Science 294, 1866-1870. crossref(new window)

9.
Duester, G. 2008. Retinoic acid synthesis and signaling during early organogenesis. Cell 134, 921-931. crossref(new window)

10.
Freemantle, S. J., Spinella, M. J. and Dmitrovsky, E. 2003. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22, 7305-7315. crossref(new window)

11.
Germain, P., Iyer, J., Zechel, C. and Gronemeyer, H. 2002. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192. crossref(new window)

12.
Glass, C. K. 1994. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15, 391-407.

13.
Gomaa, M. S., Yee, S. W. and Milbourne, C. E. 2007. “Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding”. J. Enzyme Inhib. Med. Chem. 21, 361-369.

14.
Klaassen, I., Brakenhoff, R. H., Smeets, S. J., Snow, G. B. and Braakhuis, B. J. 2001. Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br. J. Cancer 85, 630-635. crossref(new window)

15.
Loudig, O., Babichuk, C., White, J., Abu-Abed, S., Mueller, C. and Petkovich, M. 2000. Cytochrome P450RAI (CYP26) promoter: a distinct composite retinoic acid response element underlies the complex regulation of retinoic acid metabolism. Mol. Endocrinol. 14, 1483-1497. crossref(new window)

16.
Loudig, O., Maclean, G. A., Dore, N. L., Luu, L. and Petkovich, M. 2005. Transcriptional co-operativity between distant retinoic acid response elements in regulation of CYP26A1 inducibility. Biochem. J. 392, 241-248. crossref(new window)

17.
Maden, M. 2000. The role of retinoic acid in embryonic and post-embryonic development. Proc. Nutr. Soc. 59, 65-73. crossref(new window)

18.
Maeng, S., Kim, G. J., Choi, E. J., Yang, H. O., Lee, D. S. and Sohn, Y. C. 2012. 9-Cis-retinoic acid induces growth inhibition in retinoid-sensitive breast cancer and sea urchin embryonic cells via retinoid X receptor α and replication factor C3. Mol. Endocrinol. 26, 1821-1835. crossref(new window)

19.
Mongan, N. P. and Gudas, L. J. 2007. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 75, 853-870. crossref(new window)

20.
Orfanos, C. E., Zouboulis, C. C., Almond-Roesler, B. and Geilen, C. C. 1997. Current use and future potential role of retinoids in dermatology. Drugs 53, 358-388. crossref(new window)

21.
Osanai, M. and Petkovich, M. 2005. Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol. Pharmacol. 67, 1808-1817. crossref(new window)

22.
Ozpolat, B., Mehta, K., Tari, A. M. and Lopez-Berestein, G. 2002. All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am. J. Hematol. 70, 39-47. crossref(new window)

23.
Ray, M. K., Chen, C. Y., Schwartz, R. J. and DeMayo, F. J. 1996. Transcriptional regulation of a mouse Clara cell-specific protein (mCC10) gene by the NKx transcription factor family member thyroid transcription factor 1 and cardiac muscle-specific homeobox protein (CSX). Mol. Cell. Biol. 16, 2056-2064. crossref(new window)

24.
Ray, W. J., Bain, G., Yao, M. and Gottlieb, D. I. 1997. CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J. Biol. Chem. 272, 18702-18708. crossref(new window)

25.
Rohwedel, J., Guan, K. and Wobus, A. M. 1999. Induction of cellular differentiation by retinoic acid in vitro. Cells Tissues Organs 165, 190-202. crossref(new window)

26.
Ross, A. C. and Zolfaghari, R. 2011. Cytochrome P450s in the regulation of cellular retinoic acid metabolism. Annu. Rev. Nutr. 31, 65-87. crossref(new window)

27.
Rossetti, D., Kielmanowicz, M., Vigodman, S., Hu, Y., Chen, N., Nkengne, A. O. T., Fischer, D., Seiberg, M. and Lin, C. 2011. A novel anti-ageing mechanism for retinol: induction of dermal elastin synthesis and elastin fibre formation. Int. J. Cosmet. Sci. 33, 62-69. crossref(new window)

28.
Tang, X. H. and Gudas, L. J. 2011. Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 6, 345-364. crossref(new window)

29.
Thatcher, J. E. and Isoherranen, N. 2009. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin. Drug Metab. Toxicol. 5, 875-886. crossref(new window)

30.
Uehara, M., Yashiro, K., Mamiya, S., Nishino, J., Chambon, P., Dolle, P. and Sakai, Y. 2007. CYP26A1 and CYP26C1 cooperatively regulate anterior-posterior patterning of the developing brain and the production of migratory cranial neural crest cells in the mouse. Dev. Biol. 302, 399-411. crossref(new window)

31.
Van Heusden, J., Wouters, W., Ramaekers, F. C., Krekels, M. D., Dillen, L., Borgers, M. and Smets, G. 1998. The anti-proliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br. J. Cancer 77, 1229-1235. crossref(new window)

32.
Yamamoto, Y., Zolfaghari, R. and Ross, A. C. 2000. Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats. FASEB J. 14, 2119-2127. crossref(new window)

33.
Zhang, H., Satyamoorthy, K., Herlyn, M. and Rosdahl, I. 2003. All-trans retinoic acid (atRA) differentially induces apoptosis in matched primary and metastatic melanoma cells --a speculation on damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 24, 185-191. crossref(new window)

34.
Zhang, M., Chen, W. G., Smith, S. M. and Napoli, J. L. 2001. Molecular characterization of a mouse short chain dehydrogenase/reductase active with all-trans-retinol in intact cells, mRDH1. J. Biol. Chem. 276, 44083-44090. crossref(new window)